Violet Therapeutics
Stub active Updated May 18, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Violet Therapeutics is a Norwalk, Connecticut-based preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapping disease-relevant cell-to-cell signaling interactions in the brain 1. Its proprietary CONNECT platform is designed to identify therapeutically actionable signaling pathways that drive neuroinflammation, neurodegeneration, and synaptic loss; the lead program targets EphB3, a receptor tyrosine kinase that mediates microglia–astrocyte signaling implicated in glial dysfunction and synaptic loss across multiple neurodegenerative diseases 1. CEO Meredith Fisher is also a Partner at Mass General Brigham Ventures 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-18 | Seed Extension | $4.75M | Lifespan Vision Ventures | Dementia Discovery Fund, UTEC, Ono Venture Investment, Mass General Brigham Ventures 1 |
What Investors Say
Altar Munis, Associate at Lifespan Vision Ventures, said: “Preserving cognitive function is one of the most important challenges in aging biology, and Violet is approaching that challenge from a uniquely actionable angle.” 1
What Founders Say
Meredith Fisher, CEO of Violet Therapeutics, said: “We are pleased to welcome LVV as the lead investor in this extension round. LVV brings deep sector expertise in technologies that will impact diseases of aging and cognition.” 1